Exploring the potential of Fargesin from Chrysanthemum indicum for chronic migraine: in-silico and pharmacokinetic study

Rapuru Rushendran, Vellapandian Chitra · 2024

Read Exploring the potential of Fargesin from Chrysanthemum indicum for chronic migraine: in-silico and pharmacokinetic study by Rapuru Rushendran, Vellapandian Chitra (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11581172.txt.

Description

Rapuru Rushendran and Vellapandian Chitra probe, in a 2024 study, a plant compound as a candidate drug for chronic migraine. The illness ranks among the most disabling long-term ills in the world. Its core driver is a worn, over-sharp pain hub in the brain stem. Key marks of the disease span swelling signals and a peptide called CGRP; drugs that block CGRP work well for many. The plant, Chrysanthemum indicum, is a folk herb, but no proof sets it as a migraine care.

The compound, fargesin, was tested in computer models and lab checks, not in people. Dock tests showed it binds CGRP and a key enzyme with force. Body-use checks found strong uptake from the gut and good reach to the brain. Toxic checks looked kind. The pair calls it a lead worth more work, not a proven care.

Catalog record

CREATORRapuru Rushendran, Vellapandian Chitra
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11581172

Browse the full library · About the Tower of Babel